Vor Biopharma (VOR) Operating Leases (2020 - 2026)

Vor Biopharma (VOR) has 7 years of Operating Leases data on file, last reported at $2.6 million in Q1 2026.

• Operating Leases for Q1 2026 came in at $2.6 million, down 90.07% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.6 million (down 90.07% YoY), and the FY2025 annual result was $2.7 million, down 90.15% from the prior year.
• Operating Leases fell to $2.6 million in Q1 2026 per VOR's latest filing, from $2.7 million in the prior quarter.
• Over five years, Operating Leases peaked at $37.4 million in Q2 2022 and troughed at $2.6 million in Q1 2026.
• A 5-year average of $26.0 million and a median of $30.2 million in 2024 frame the typical range for Operating Leases.
• The sharpest annual moves came in 2022 and 2025: Operating Leases surged 123.41% in 2022, then tumbled 90.22% in 2025.
• A 5-year view of Operating Leases shows it stood at $35.6 million in 2022, then retreated by 10.69% to $31.8 million in 2023, then fell by 13.24% to $27.6 million in 2024, then plunged by 90.15% to $2.7 million in 2025, then declined by 3.24% to $2.6 million in 2026.
• Business Quant data shows VOR's Operating Leases at $2.6 million in Q1 2026, $2.7 million in Q4 2025, and $2.8 million in Q3 2025.